Skip to main content

Table 3 Preclinical studies based on the use of TALEN and ZFN technologies to provide more effective and universal CAR-T cell

From: A deep insight into CRISPR/Cas9 application in CAR-T cell-based tumor immunotherapies

Condition

CAR

Target locus (knocked out)

Study model

Ref

TALEN

MM

BCMA

CD20

MM.1S cell line

NSG mice

[129]

B-ALL

CD19

TRAC

CD52

NSG mice

[130, 131]

BL

CD22

TRAC

CD25

PD-1

RAJI cell line

NSG mice

[132]

T-ALL

CD3

TRAC

Jurkat cell line

NSG mice

[133]

B-ALL

CD20

TRAC

PD-1

Cell line

[134]

BL

CD22

GM-CSF

RAJI and Daudi cell line

[135]

B-ALL

CD19

TRAC

CD52

NALM6 cell line

NSG mice

[136]

ZFN

B-ALL

CLL

MCL

CD19

TRAC

Primary tumor cells

[126]

B-ALL

CD19

TRAC

Cell line

[7]

  1. Note: ALL acute lymphoblastic leukemia, BCMA B cell maturation antigen, TRAC T cell receptor alpha constant, PDCD1 or PD1 programmed cell death protein 1, GM-CSF granulocyte-macrophage colony-stimulating factor, MM multiple myeloma, MCL mantle cell lymphoma, BL Burkitt’s lymphoma